An aggressive approach to marginally resectable lung cancer.
Between July 1968 and December 1974, 53 patients with lung cancer were planned for preoperative irradiation and surgery. All patients were considered clinically marginally resectable because of advanced local disease, 4 Stage II patients, with limited pulmonary reserve and 49 Stage III patients. Most patients received 3000 to 4000 rad followed in two weeks by thoracotomy. Forty-six patients were explored and 38 were resectable. Twelve patients are alive with a median follow-up of 48 months. The cumulative 5-year survival of all resectable patients is 27%. The survival of patients with marginally resectable lung cancer treated by accelerated radiotherapy followed by aggressive surgery approaches the survival experience of patients with primary resectable lung cancer and is superior to such patients treated with radiation therapy alone.
D001983:Bronchial Fistula / Q000209:etiology; D002294:Carcinoma, Squamous Cell / Q000628:therapy; D004653:Empyema / Q000209:etiology; D005260:Female; D006469:Hemoptysis / Q000209:etiology; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D008297:Male; D010995:Pleural Diseases / Q000209:etiology; D011183:Postoperative Complications / Q000209:etiology; D011832:Radiation Injuries / Q000209:etiology; D011882:Radiotherapy, High-Energy / Q000009:adverse effects; D012075:Remission, Spontaneous; D013997:Time Factors